• 提示：詳情請下載說明書。

• 產品描述： ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.

• 靶點： Autophagy Microtubule Associated;MicrotubuleAssociated;Autophagy

• 體內研究：
  ABT-751顯示出對動態(tài)微管的選擇性作用并且保留穩(wěn)定的微管,從而解釋了在ABT-751的IC90濃度下乙?；腿ダ野彼幡?微管蛋白陽性聚合小管的持久性。在體外,ABT-751顯示選擇性細胞毒性,在神經母細胞瘤中IC50為0.6-2.6 μM,在其他實體瘤細胞系中為0.7-4.6 μM

• 細胞實驗： Cells, in 1640 RPMI media with FBS, are plated in triplicate onto 96 well tissue culture plates in numbers determined optimal for confluent monolayer growth (5,000 cells/well for HOS, HTB-186 Daoy; 10,000 cells/well for TC-71, RD, SK-N-AS, SK-N-DZ, LD; 30,000 cells/well for KCNR), with an automated, multichannel pipette system. Cells are incubated for 24 hours at 37 °C/5% CO2 then exposed to vehicle control (1.25% DMSO/Water), VCR (0.1–1000 nM), ABT-751 (0.1 nM–100 μM), and in 4 cell lines (SK-N-AS, KCNR, RD, TC-71) combretastatin (0.1–1000 nM) for 72 hours. Cells are fixed with trichloroacetic acid (final concentration 10%) at 4 °C, washed, then dried at room temperature, stained with SRB in 1% acetic acid and dye is then solubilized with Tris base. Optical density measurements are performed at 540 and 405 nm dual wavelengths in a Bio-Tek EL 340 UV plate reader. (Only for Reference)

• 參考文獻：
  1.Meany HJ, et al. Pediatr Blood Cancer. 2010, 54(1), 47-54. 2.Jorgensen TJ, et al. Cancer Chemother Pharmacol. 2007, 59(6), 725-732. 3.Silver M, et al. J Vet Intern Med. 2012, 26(2), 349-354.

• 溶解性： DMSO:37.1  mg/mL  (100  mM)    Ethanol:9.3  mg/mL  (25  mM)

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.692 ml	13.462 ml	26.924 ml
  5 mM	0.538 ml	2.692 ml	5.385 ml
  10 mM	0.269 ml	1.346 ml	2.692 ml
  50 mM	0.054 ml	0.269 ml	0.538 ml

• 注意：部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。

輸入產品批號：

本計算器可幫助您計算出特定溶液中溶質的質量、溶液濃度和體積之間的關系，公式為：

質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *